1027229-90-8

Upstream product

• 597577-78-1 (4R)-4-t-butoxycarbonylamino-5-hydroxypentanoic acid ethyl ester 
• 494224-49-6 (R)-ethyl 4-(tert-butoxycarbonylamino)-5-oxopentanoate 
• 1260900-49-9 methyl 2-[3-(2-hydroxyethyl)phenyl]acetate 
• 1365177-41-8 C₂₁H₃₀ClNO₅ 
• 1365177-51-0 methyl [3-(2-bromoethyl)phenyl]acetate 
• 1365177-44-1 ethyl (4R,5E,7S)-4-amino-8-(3-chlorophenyl)-7-hydroxy-5-octenoate trifluoroacetate 
• 1365178-52-4 ethyl (4R,5E)-8-(3-chlorophenyl)-4-({[(2-methyl-2-propanyl)oxy]carbonyl}amino)-7-oxo-5-octenoate 
• 1365177-48-5 methyl [3-(2-{(2R)-2-[(1E,3S)-4-(3-chlorophenyl)-3-hydroxy-1-buten-1-yl]-5-oxo-1-pyrrolidinyl}ethyl)phenyl]acetate 
• 19806-17-8 1,3-benzenediacetic acid 

Relevant academic research and scientific papers

Discovery of novel prostaglandin analogs as potent and selective EP2/EP4 dual agonists

To identify potent EP2/EP4 dual agonists with excellent subtype selectivity, a series of γ-lactam prostaglandin E analogs bearing a 16-phenyl ω-chain were synthesized and evaluated. Structural hybridization of 1 and 2, followed by more detailed chemical m

REMEDIES FOR DISEASES WITH BONE MASS LOSS HAVING EP sb 4 /sb AGONIST AS THE ACTIVE INGREDIENT

A pharmaceutical composition for topical administration for prevention and/or treatment of diseases associated with decrease in bone mass comprising an EP4 agonist as an active ingredient. An EP4 agonist, in which includes a compound